Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
Más filtros

Medicinas Complementárias
Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Biol Pharm Bull ; 45(11): 1669-1677, 2022.
Artículo en Inglés | MEDLINE | ID: mdl-36328503

RESUMEN

Although paliperidone-related hyperglycemia has been extensively examined, the underlying mechanisms have not yet been elucidated. We investigated the effects of a single intravenous injection of paliperidone (0.2, 0.4, or 0.6 mg/kg) on serum concentrations of glucose and other endogenous metabolites in rats. We also examined the effects of a single intravenous injection of paliperidone (0.4 mg/kg) on AMP-activated protein kinase (AMPK) activity in the hypothalamus and liver. To clarify the relationship between AMPK activity and adrenaline secretion, the effects of berberine, which inhibits hypothalamic AMPK, on paliperidone-induced hyperglycemia were assessed. Significant increases were observed in serum glucose, adrenaline, and insulin concentrations following intravenous injections of paliperidone at doses of 0.4 and 0.6 mg/kg. A propranolol pretreatment attenuated paliperidone-induced increases in serum concentrations of glucose, but not adrenaline. Significant increases were also noted in phosphorylated AMPK concentrations in the hypothalamus following the administration of paliperidone at a dose of 0.4 mg/kg. A berberine pretreatment attenuated paliperidone-induced increases in blood concentrations of glucose, adrenaline, and insulin and phosphorylated AMPK concentrations in the hypothalamus. Collectively, the present results demonstrated that an acute treatment with paliperidone induced hyperglycemia, which was associated with the effects of hypothalamic AMPK activation on the secretion of adrenaline.


Asunto(s)
Berberina , Hiperglucemia , Ratas , Animales , Proteínas Quinasas Activadas por AMP/metabolismo , Palmitato de Paliperidona/farmacología , Berberina/farmacología , Berberina/uso terapéutico , Hiperglucemia/inducido químicamente , Hiperglucemia/metabolismo , Hipotálamo/metabolismo , Insulina , Glucosa/metabolismo
2.
Sci Rep ; 10(1): 4864, 2020 03 17.
Artículo en Inglés | MEDLINE | ID: mdl-32184468

RESUMEN

Excessive phosphorus intake adversely affects bone and mineral metabolism. Estrogen is one of the factors affecting fibroblast growth factor 23 (FGF23), a phosphorus-regulating hormone. However, the interaction between excess phosphorus and estrogen status has not been fully elucidated. This study investigated the involvement of estrogen in the effects of high phosphorus intake on bone metabolism and ectopic calcification in ovariectomized (OVX) rats. The interaction between high phosphorus diet and OVX was not observed in bone mineral density and aortic calcium. In contrast, high phosphorus intake markedly increased renal calcium concentration in sham rats, whereas the effect was attenuated in OVX rats, which was reversed by a selective estrogen-receptor modulator treatment. A strong positive correlation between renal calcium and serum FGF23 was observed. In addition, fibroblast growth factor receptor 1 (FGFR1: a predominant receptor of FGF23) inhibitor treatment partially decreased renal calcium concentrations in rats with high phosphorus intake. In conclusion, the effect of high phosphorus intake on bone metabolism and aortic calcification did not depend on the estrogen status; in contrast, high phosphorus intake synergistically induced nephrocalcinosis in the presence of estrogenic action on the bone. Furthermore, FGF23 was involved in the nephrocalcinosis induced by high phosphorus intake partially through FGFR1 signaling.


Asunto(s)
Estrógenos/metabolismo , Factores de Crecimiento de Fibroblastos/sangre , Nefrocalcinosis/metabolismo , Fósforo/efectos adversos , Receptor Tipo 1 de Factor de Crecimiento de Fibroblastos/metabolismo , Animales , Aorta/metabolismo , Densidad Ósea/efectos de los fármacos , Calcio/metabolismo , Modelos Animales de Enfermedad , Femenino , Factores de Crecimiento de Fibroblastos/efectos de los fármacos , Nefrocalcinosis/sangre , Nefrocalcinosis/inducido químicamente , Ovariectomía/efectos adversos , Pirimidinas/farmacología , Clorhidrato de Raloxifeno/farmacología , Ratas
3.
Nutrients ; 8(10)2016 Oct 21.
Artículo en Inglés | MEDLINE | ID: mdl-27775655

RESUMEN

The aim of this study was to investigate the effects of proton pump inhibitor (PPI), the most potent acid-suppressing drug, administration and intake of a combination of yogurt and galactooligosaccharides (YG) on bone and mineral metabolism in adult rats. Twelve-week-old male Wistar rats were divided into three groups: a control group fed the control diet with vehicle administration, a PPI group fed the control diet with PPI administration and a YG + PPI group fed the YG diet with PPI administration. All of the groups received their respective experimental diets and daily subcutaneous injection of the vehicle or PPI for 12 weeks. The PPI group showed significantly lower bone mineral density (BMD) of the femur and the lumbar vertebrae and serum fibroblast growth factor 23 (FGF23) and significantly higher phosphorus absorption and serum 1,25-dihydroxyvitamin D (1,25(OH)2D) than the control group, although PPI did not affect calcium absorption. The PPI + YG group showed significantly higher BMD and serum FGF23 and significantly lower phosphorus absorption and serum 1,25(OH)2D than the PPI group. Furthermore, the PPI + YG group showed higher calcium absorption than the control group. These results suggest that although PPI administration did not affect calcium absorption, it adversely affected BMD and influenced phosphorus metabolism in adult rats. Furthermore, the YG diet beneficially affected BMD and attenuated the effects of PPI administration on phosphorus metabolism.


Asunto(s)
Densidad Ósea , Huesos/efectos de los fármacos , Calcio de la Dieta/sangre , Oligosacáridos/farmacología , Fósforo/sangre , Inhibidores de la Bomba de Protones/efectos adversos , Yogur , Animales , Huesos/metabolismo , Calcio de la Dieta/farmacología , Dieta , Fémur/efectos de los fármacos , Fémur/metabolismo , Factor-23 de Crecimiento de Fibroblastos , Factores de Crecimiento de Fibroblastos/sangre , Galactosa , Vértebras Lumbares/efectos de los fármacos , Vértebras Lumbares/metabolismo , Masculino , Minerales/sangre , Omeprazol/efectos adversos , Ratas Wistar , Vitamina D/análogos & derivados , Vitamina D/sangre , Yogur/microbiología
4.
J Appl Physiol (1985) ; 121(4): 1021-1031, 2016 10 01.
Artículo en Inglés | MEDLINE | ID: mdl-27197855

RESUMEN

In Japan, the incidence of heat illness in older people has rapidly increased during midsummer in the last decade, and we suggested that whey-protein+carbohydrate supplementation during aerobic training would increased plasma volume (PV) to enhance thermoregulatory adaptation in older men (J Appl Physiol 107: 725-733, 2009); however, >60% of people age 65 and older suffer from hypertension, and the symptoms may be worsened by hypervolemia. To examine this, we randomly divided 21 older men (∼69 yr) with ∼160 mmHg for systolic and ∼90 mmHg for diastolic blood pressure at rest into two groups: Glc (n = 11) consuming glucose alone (25 g) and Pro-Glc (n = 10) consuming whey protein (10 g) + glucose (15 g), immediately after cycling exercise at 60-75% of peak aerobic capacity (V̇o2 peak) for 60 min/day, 3 days/wk, for 8 wk. Before and after training, we measured PV (dye dilution), baroreflex sensitivity (BRS) of heart rate (Valsalva maneuver), and carotid arterial compliance (CAC) from carotid arterial diameter (ultrasound imaging) responses to pulsatile arterial pressure change (photoplethysmography) at rest. Additionally, we measured esophageal temperature (Tes) and forearm skin blood flow (plethysmography) during exercise at 60% pretraining V̇o2 peak for 20 min in a warm environment. We found that the forearm skin vascular conductance response to increased Tes was enhanced in Pro-Glc with increased PV, but this was not found in Glc; however, despite the increased PV, arterial blood pressures rather decreased with increased CAC and BRS in Pro-Glc. Thus, the prescription was applicable to older men with hypertension to prevent heat illness during exercise.


Asunto(s)
Presión Arterial/efectos de los fármacos , Regulación de la Temperatura Corporal/efectos de los fármacos , Proteínas en la Dieta/administración & dosificación , Terapia por Ejercicio/métodos , Glucosa/administración & dosificación , Hipertensión/tratamiento farmacológico , Volumen Plasmático/efectos de los fármacos , Administración Oral , Anciano , Barorreflejo/efectos de los fármacos , Suplementos Dietéticos , Humanos , Hipertensión/fisiopatología , Masculino
5.
J Nutr Sci Vitaminol (Tokyo) ; 60(2): 140-4, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-24975224

RESUMEN

Oral phosphorus supplementation stimulates fibroblast growth factor 23 (FGF23) secretion; however, the underlying mechanism remains unclear. The aim of this study was to investigate the involvement of parathyroid hormone (PTH) in increased plasma FGF23 levels after oral phosphorus supplementation in rats. Rats received single dose of phosphate with concomitant subcutaneous injection of saline or human PTH (1-34) after treatment with cinacalcet or its vehicle. Cinacalcet is a drug that acts as an allosteric activator of the calcium-sensing receptor and reduces PTH secretion. Plasma phosphorus and PTH levels significantly increased 1 h after oral phosphorus administration and returned to basal levels within 3 h, while plasma FGF23 levels did not change up to 2 h post-treatment, but rather significantly increased at 3 h after administration and maintained higher levels for at least 6 h compared with the 0 time point. Plasma PTH and FGF23 levels were significantly lower in the cinacalcet-treated rats than in the vehicle-treated rats. Plasma phosphorus levels were significantly higher in the cinacalcet-treated rats than in the vehicle-treated rats at 2, 3, 4, and 6 h after oral phosphorus administration. Furthermore, rats treated with cinacalcet+human PTH (1-34) showed transiently but significantly higher plasma FGF23 levels at 3 h after oral phosphorus administration compared with cinacalcet-treated rats. These results suggest that oral phosphorus supplementation secondarily increases circulating FGF23 levels at least partially by stimulation of PTH secretion.


Asunto(s)
Suplementos Dietéticos , Factores de Crecimiento de Fibroblastos/sangre , Hormona Paratiroidea/metabolismo , Fósforo Dietético/farmacología , Fósforo/farmacología , Animales , Cinacalcet , Femenino , Factor-23 de Crecimiento de Fibroblastos , Humanos , Naftalenos/farmacología , Fosfatos/sangre , Fosfatos/farmacología , Fósforo/sangre , Fósforo Dietético/sangre , Ratas Wistar , Receptores Sensibles al Calcio/metabolismo
6.
Biosci Biotechnol Biochem ; 78(5): 861-6, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-25035990

RESUMEN

To examine the effect of dietary supplementation with 1-kestose on the IgA levels in milk, BALB/c mice were fed diets with or without 5% 1-kestose during pregnancy and lactation. The total and specific IgA levels in the milk were measured at 7 and 14 days after delivery. A two-way ANOVA with repeated measures resulted in a significant effect of 1-kestose-supplementation on total IgA concentrations (p < 0.05) and the level of anti-Bacteroides IgA (p < 0.05). A significant positive correlation was found between the mean count of Bacteroides spp. in maternal feces and the total IgA concentration in maternal milk (r = 0.55, p < 0.05), suggesting a potential link between the gut and mammary gland immune system. In conclusion, this study demonstrated the effects of dietary prebiotics on milk IgA production.


Asunto(s)
Inmunoglobulina A/metabolismo , Lactancia/metabolismo , Leche/efectos de los fármacos , Leche/metabolismo , Trisacáridos/farmacología , Animales , Bacteroides/inmunología , Bacteroides/fisiología , Suplementos Dietéticos , Heces/microbiología , Femenino , Inmunoglobulina A/sangre , Inmunoglobulina A/inmunología , Mucosa Intestinal/metabolismo , Intestinos/efectos de los fármacos , Intestinos/microbiología , Lactancia/efectos de los fármacos , Ratones , Ratones Endogámicos BALB C , Microbiota/efectos de los fármacos , Embarazo
7.
J Nutr Biochem ; 22(2): 172-8, 2011 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-20378322

RESUMEN

Zinc (Zn) supplementation stimulates bone growth in Zn-deficient humans and animals. A biphasic pattern of mineralization has been observed in cultured osteoblasts; an initiation phase and a progression phase. We used MC3T3-E1, a murine osteoblastic cell line, to elucidate the physiological role of Zn in osteoblast mineralization and cellular Zn trafficking during the mineralization event. Cells were cultured in media containing Chelex-treated fetal bovine serum and 1, 4, 10 and 20 µM Zn as ZnSO(4) for 14 days (early phase of mineralization) or 21 days (mid-to-late phase of mineralization). During the early phase of mineralization, Alizarin Red staining indicated that mineralization was increased by Zn in a dose-dependent manner. Although Zn exposure did not affect monolayer Zn concentration, metallothionein (MT) mRNA expression increased dose-dependently as assessed by real-time PCR. During the late phase of mineralization, mineralization was maximal at 1 µM Zn and monolayer Zn concentration reflected Zn exposure. The increase in MT mRNA expression during the late phase was similar to that during the early phase, but the difference in expression between culture Zn concentrations tended to be smaller. ZnT-2 mRNA expression decreased significantly with increasing zinc concentrations in the culture medium during the early phase, but increased significantly during the late phase. Osteocalcin mRNA levels were positively correlated to Zn exposure at both time points. Taken together, we propose that Zn may play an important role in osteoblast mineralization through Zn trafficking involving Zn storage proteins and Zn transporters.


Asunto(s)
Calcificación Fisiológica , Proteínas de Transporte de Catión/metabolismo , Suplementos Dietéticos , Osteoblastos/metabolismo , Zinc/administración & dosificación , Animales , Proteínas de Transporte de Catión/genética , Línea Celular , Metalotioneína/metabolismo , Ratones , Osteoblastos/citología , Osteocalcina/genética , Osteocalcina/metabolismo , Transporte de Proteínas , ARN Mensajero/genética , ARN Mensajero/metabolismo , Zinc/deficiencia
8.
Biosci Biotechnol Biochem ; 72(2): 406-11, 2008 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-18256496

RESUMEN

There is limited information on the effect of fruits on human cytochrome P450 (CYP) 2C9 activity. The objective of this study was to determine the effect of fruit juice on CYP2C9-mediated drug metabolism. Nine citrus fruits and eight tropical fruits were chosen. We investigated effects of the fruits on diclofenac 4'-hydroxylation and tolbutamide hydroxylation by human liver microsomes. Among the fruits, pineapple juice showed potent inhibition of CYP2C9 activity. The addition of 25 microl (5.0% v/v) of pineapple juice resulted in almost complete inhibition. Next we examined the inhibitory effect of bromelain, a cysteine protease in pineapple. Bromelain also strongly inhibited CYP2C9 activity. In addition, E-64, a cysteine protease inhibitor, almost entirely blocked inhibition by pineapple juice and bromelain. Thus we found that pineapple juice was a potent inhibitor of CYP2C9, and that the inhibitory effect might be due to the bromelain contained in pineapple.


Asunto(s)
Hidrocarburo de Aril Hidroxilasas/antagonistas & inhibidores , Bebidas , Frutas , Hidrocarburo de Aril Hidroxilasas/metabolismo , Bromelaínas/farmacología , Citocromo P-450 CYP2C9 , Microsomas Hepáticos/enzimología , Inhibidores de Proteasas/farmacología , Ultrafiltración
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA